May 28, 2017
Recommended Topic Related To:

Tigecycline Generic

"Bezlotuxumab has a similar safety profile and significantly lower rate of recurrent Clostridium difficile infection than placebo among patients receiving standard-of-care antibiotics, according to data from the phase 3 trials MODIFY I an"...

A A A

Tigecycline Generic Injection

TIGECYCLINE
for Injection

WARNING

ALL-CAUSE MORTALITY

An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline should be reserved for use in situations when alternative treatments are not suitable [see INDICATIONS AND USAGE, WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].

DRUG DESCRIPTION

Tigecycline for Injection, USP is a tetracycline class antibacterial for intravenous infusion. The chemical name of tigecycline is (4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11dioxo-2-naphthacenecarboxamide.

The following represents the chemical structure of tigecycline:

Figure 1: Structure of Tigecycline

TIGECYCLINE - Structural Formula Illustration

C29H39N5O8       M.W. 585.65

Tigecycline for injection, USP is an orange lyophilized powder or cake. Each tigecycline single dose 10 mL vial contains 50 mg tigecycline and 82.6 mg of arginine as lyophilized powder for reconstitution for intravenous infusion. The pH is adjusted with hydrochloric acid, and if necessary sodium hydroxide. The product does not contain preservatives.

Last reviewed on RxList: 1/11/2017
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.